PYPD
PolyPid Ltd.
Set alert
5.39 USD -0.20 -3.58%
5.39 Day range 5.59
3.58 52-week range 5.78
- YTD
- +24.19%
- 1 year
- +40.36%
- Open
- 5.54
- Prev close
- 5.59
- Mkt cap
- 109.48M
- Vol
- 101.56K
- Avg vol
- 118.58K
- EPS
- -1.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.39
- High
- 5.59
- Forward P/E
- -1.36
- Beta
- 1.32
- Short ratio
- 2.29
- Inst. own
- 36.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 3.28
- 200-d avg
- 3.90
- 1y target
- 11.75
Key statistics
- Market cap
- 25.04M
- Enterprise value
- 18.09M
- Trailing P/E
- 0.00
- Forward P/E
- -1.36
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -7.22
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.82M
- Total cash
- 9.35M
- Total debt
- 11.03M
- Return on equity
- -496.62%
- Shares outstanding
- 6.80M
- Short % of float
- 0.28%
- 50-day average
- 3.28
- 200-day average
- 3.90
Analyst view
Consensus: buy
Buy
Price target (mean) 11.75 +118.0% upside
Now 5.39
- Target (low)
- 10.00
- Target (mean)
- 11.75
- Target (high)
- 14.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -1.03.
Financials — quick view
PYPD Revenue — quarterly 0
PYPD Net income — quarterly -9.98M
PYPD EPS — quarterly -0.78
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -1.05 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -1.07 | -1.22 | -0.15 | -14.02% |
| Aug 14, 2024 | Jun 1, 2024 | -1.51 | -1.25 | +0.26 | +17.22% |
| Aug 14, 2024 | Jun 1, 2024 | -1.51 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.96 | -1.37 | +0.59 | +30.10% |
| May 8, 2024 | Mar 1, 2024 | -1.96 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | Craig-Hallum | init | — | Buy |
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About PolyPid Ltd.
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polypid.com
News
- This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
- This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
- PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
- This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Oppenheimer Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $10
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
Your note
Sign in to keep a note on PYPD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.99% | 679,668 | 2.50M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 9.98% | 679,168 | 2.50M | Sep 29, 2024 |
| DAFNA Capital Management, LLC | 4.53% | 308,497 | 1.14M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.04% | 138,504 | 509.69K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.38% | 93,902 | 345.56K | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 0.16% | 11,153 | 41.04K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 80 | 294 | Oct 30, 2024 |